JAJamal Ali Ashoor

Jamal Ali Ashoor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jamal Ali Ashoor has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Formulation and Characterization of Lipophilic Chemotherapy as Ethosomal Gel for Cervical Cancer

    by Maryam Alaayedi, Zahraa Mohammed Kadhim, Jamal Ali Ashoor, Ashti Mh Saeed, Jinan M Al-Mousawy, Hasanain Shakir Mahmood, Entsar H. Jawad, Mustafa H. Alhamadani

    Aim: methotrexate was formulated as Ethosomal gel for enhancing the therapeutic performance and stability to treat cervical cancer via targeting the drug locally through cervical mucosa to avoid the systemic adverse effect of the chemotherapy. Materials and Methods: The formulations were produced using phospholipid and cholesterol then evaluated for particle size, polydispersity index, zeta potential, pH and drug release. The optimized ethosome formula then converted to gel. The gel evaluated for organoleptic properties, pH, viscosity and permeability. Results: The results showed than F8 was the best ethosomal formula with 34nm in size and 92% entrapment efficiency. This formula converted into gel had 1% gelling agent that was optimized ethosomal gel formula and gave better release that ordinary methotrexate gel with same type and percent of gelling agent. Conclusions: The drug was successfully formulated as ethosomal gel for treating cervical cancer topically in order to avoid the systemic exposure for the chemotherapy and its consequence adverse effect.

  • Open Access

    Topical Astaxanthin Attenuates Imiquimod-Induced Psoriasiform Dermatitis by Downregulating Psoriasis-Associated Keratin Gene Expression (Krt16, Krt17, Krt6a) and Inhibiting the JAK-STAT Signaling Pathway

    by Waleed Khaled Younis Albahadly, Haider Falih Shamikh Al-Saedi, Jamal Ali Ashoor, Mohammed Ibrahim Rasool, Samer Ali Hasan, Meeqaat H. Altrufi

    Psoriasis is a chronic immune-mediated inflammatory skin disorder characterized by excessive keratinocyte proliferation, oxidative stress, and dysregulated cytokine signaling. Although topical corticosteroids remain the first-line therapy, their long-term use is often limited by adverse effects, highlighting the need for safer non-steroidal therapeutic alternatives. This study investigated the therapeutic efficacy and underlying mechanisms of a topical astaxanthin (AST) formulation in an imiquimod (IMQ)-induced mouse model of psoriasiform dermatitis. Following IMQ induction, mice were randomly assigned to vehicle, clobetasol, or AST treatment groups (0.5–1.5%) for 14 days. Disease progression was evaluated through biochemical analysis of oxidative stress biomarkers, including NADPH oxidase (NOX), malondialdehyde (MDA), nitric oxide (NO), and superoxide dismutase (SOD), as well as ELISA-based quantification of inflammatory cytokines (TNF-α, IL-6, IL-17, and IL-23). Histopathological changes were assessed using hematoxylin and eosin staining, while molecular alterations were examined by RT-qPCR analysis of psoriasis-associated keratin genes (Krt16, Krt17, and Krt6a) and evaluation of JAK–STAT signaling activity. AST treatment significantly suppressed the IL-23/IL-17 inflammatory axis, reduced NOX activity and lipid peroxidation, restored endogenous antioxidant defenses, and inhibited JAK–STAT signaling. These biochemical and molecular effects were accompanied by marked downregulation of keratin gene expression and substantial histological improvement, including normalization of epidermal thickness, reduced parakeratosis, and decreased inflammatory infiltration. Notably, high-dose AST demonstrated therapeutic efficacy comparable to, and in some parameters exceeding, that of clobetasol. Collectively, these findings indicate that topical astaxanthin exerts coordinated antioxidant, anti-inflammatory, and anti-proliferative effects, supporting its potential as a promising multi-target non-steroidal therapeutic candidate for psoriasis management.


  • Open Access

    Enhancing the Solubility of Class II Drug Via Nanosuspension: A Review

    by Ansam Falah Abbas, Jamal Ali Ashoor, Maryam H. Alaayedi

    Poor aqueous solubility remains a significant challenge in drug development, particularly for biopharmaceutics classification system, a promising approach to enhance solubility and dissolution by reducing particle size and increasing surface area. This review explores the formulation and evaluation of nanosuspensions as an effective strategy to improve the bioavailability of poorly water-soluble drugs. Various techniques, including top-down and bottom-up methods, contribute to nanosuspension preparation, with high- pressure homogenization and media milling being the most widely used. Selection of stabilizers plays a crucial role in preventing aggregation and ensuring long-term stability. Characterization parameters such as particle size, zeta potential, drug content, and in vitro dissolution provide critical insights in to nanosuspension performance. Recent advancements in nanosuspension technology enable enhanced therapeutic efficacy, reduced dosing frequency, and improved patient compliance. Applications extend to oral, parenteral, and ophthalmic drug delivery, offering versatility in pharmaceutical formulations. Challenges related to physical stability, scalability, and regulatory considerations require further investigation to facilitate commercialization. Future research focuses on optimizing formulation techniques, exploring novel stabilizers, and integrating advanced analytical tools for better characterization. Nanosuspensions continue to demonstrate potential in overcoming solubility limitations and enhancing drug absorption, making them a valuable approach in pharmaceutical development.